AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide. This makes it the most widely used of all devices for excluding the left atrial appendage (LAA), according to the company.

April 24, 2017 — Offering a full range of advanced clinical applications for researchers, Toshiba Medical will demonstrate the Vantage Galan 3T, at the 2017 International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting, April 22-27 in Honolulu, Hawaii.

I keep close watch on our magazine’s digital analytics for both our website and social media, and it shows me in real time what readers think are the hottest topics in cardiac technology. Here is a top 5 list of some of the most note-worthy recent news items:

1. FDA Harshly Criticizes Abbott, St. Jude For Failure to Address EP Device Safety

A recent study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France validated the advantages of the Niobe ES magnetic navigation system over the Niobe II system in terms of procedure and fluoroscopy times for atrial fibrillation (AF) ablation procedures. The study was published in the International Journal of Cardiology and represents the first comparison study of Stereotaxis’ latest-generation remote magnetic navigation system to its predecessor.

Physio-Control announced April 19 that the company’s HeartSine samaritan PAD 360P (SAM 360P) fully automatic external defibrillator (AED) is now available for sale in the United States, having received U.S. Food and Drug Administration (FDA) premarket approval (PMA).

The Structural Heart Program at Princeton Baptist Medical Center, (Birmingham, Ala.) recently became the first center in the Southeast to implant the newly U.S. Food and Drug Administration (FDA)-approved CoreValve Evolut Pro.

April 20, 2017 — Mitral regurgitation can occur in up to 50 percent of patients with ischemic heart disease and even mild ischemic mitral regurgitation (IMR) has been linked to increased long-term mortality. How best to treat IMR is controversial, in part, because of the fragility and complexity of the patients, difficulty of grading IMR, the variety of medical and surgical options, and lack of long-term quality studies.

Cardiovascular Systems Inc. (CSI) announced April 18 it had initiated a voluntary recall of its 7-10014 Saline Infusion Pump. CSI initiated a customer communication of the recall by letter and informed customers that they may continue to use the affected Saline Infusion Pumps until they receive a replacement.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now